[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lower-urinary-tract-symptom\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lower-urinary-tract-symptom":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,74,100,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100640806","a-prospective-comparative-study-evaluating-the-safety-and-efficacy-of-transurethral-thulium-fiber-laser-holmium-laser-and-bipolar-enucleation-of-large-sized-prostate-100640806",false,"NCT07627178","A Prospective Comparative Study Evaluating the Safety and Efficacy of Transurethral Thulium Fiber Laser, Holmium Laser and Bipolar Enucleation of Large Sized Prostate","Inclusion Criteria:\n\n* Male patients diagnosed with BPH\n* Clinical diagnosis of BPH with lower urinary tract symptoms.\n* IPSS ≥ 20 (severe symptoms)\n* Maximum urinary flow rate (Qmax) ≤ 10 mL\u002Fs\n* Prostate volume \\>100 mL (measured by transrectal ultrasound)\n* Failed medical therapy and fit for operation\n\nExclusion Criteria:\n\n* Prostate cancer (current or history).\n* Previous prostate surgery\n* Previous urethral surgery.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection.\n* Severe cardiovascular disease (ASA Class IV).\n* Previous pelvic radiation.\n* Urethral stricture\n* Urinary bladder stones.",true,"MALE",{"count":18,"type":19},90,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study compares the safety and efficacy of three endoscopic enucleation techniques for large prostates (\\>100 mL) in patients with benign prostatic hyperplasia (BPH): Thulium Fiber Laser Enucleation (ThuFLEP), Holmium Laser Enucleation (HoLEP), and Bipolar Enucleation (B-TUEP). Ninety male patients with severe lower urinary tract symptoms (IPSS ≥20, Qmax ≤10 mL\u002Fs) who failed medical therapy will be randomized 1:1:1 into three groups of 30. Primary outcomes include IPSS, quality of life score, maximum flow rate (Qmax), and post-void residual at 1, 3, and 6 months postoperatively. Secondary outcomes include operative time, enucleation efficiency, blood loss, catheterization duration, hospital stay, and complication rates assessed by the Clavien-Dindo classification.",[25,26,27],"Benign Prostatic Hyperplasia (BPH)","Lower Urinary Tract Symptom","Bladder Outlet Obstruction",[29,30,31,32,33,34,35,36],"Prostate Enucleation","ThuLEP","HOLEP","Bi-TUEP","TFL","BPH Surgery","IPSS","Uroflowmetry","RECRUITING","2026-06-03",{"date":40,"type":41},"2026-06-05","ACTUAL",{"date":43,"type":41},"2025-10-21",{"date":45,"type":19},"2027-05-30",{"name":47,"class":48},"Tanta University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100625003","urinary-ctgf-in-benign-prostatic-obstruction-100625003","NCT07416981","Urinary CTGF in Benign Prostatic Obstruction","The Relationship of Urinary CTGF Levels With Bladder Fibrosis and Surgical Treatment Response in Patients With Benign Prostatic Obstruction","Inclusion Criteria:\n\nMale patients aged \\> 40 years\n\n* Diagnosis of benign prostatic obstruction (BPO), with or without an indwelling catheter\n* Patients with an indication for surgical treatment according to EAU guidelines\n\nExclusion Criteria:\n\n* Age \\\u003C 40 years\n* Female sex\n* Prostate-specific antigen (PSA) \\> 2.5 ng\u002FmL\n* History of endoscopic urological intervention\n* Previous urogenital malignancy or urological surgery\n* Diabetes mellitus\n* Urethral stricture\n* History of pelvic radiotherapy and\u002For chemotherapy\n* Patients performing clean intermittent catheterization\n* Neurological diseases causing secondary urinary symptoms (e.g., spinal cord injury, stroke, multiple sclerosis, Parkinson's disease)\n* History of spinal surgery\n* History of colorectal cancer or previous colorectal surgery","40 Years",{"count":59,"type":19},50,"OBSERVATIONAL","Benign prostatic obstruction (BPO) is one of the most common causes of bladder outlet obstruction (BOO) and may lead to progressive structural and functional alterations in the bladder over time. Prolonged obstruction triggers a bladder remodeling process characterized by detrusor hypertrophy, ischemia-reperfusion injury, smooth muscle loss, and progressive fibrosis. These pathological changes may result in impaired detrusor contractility, increased post-void residual volume, and suboptimal functional recovery following surgical treatment.\n\nConnective tissue growth factor (CTGF) is a matricellular protein that plays a key role in fibrogenesis and is markedly upregulated under hypoxic, ischemia-reperfusion, and inflammatory conditions. Experimental and cellular studies have demonstrated that CTGF promotes fibroblast proliferation, extracellular matrix production, and collagen deposition, thereby contributing to bladder fibrosis. Increased CTGF expression has also been associated with fibrotic differentiation of bladder smooth muscle cells.\n\nThe aim of this observational study is to evaluate the relationship between urinary CTGF levels, bladder fibrosis, and functional response to surgical treatment in patients with benign prostatic obstruction. Preoperative urinary CTGF levels will be assessed and correlated with postoperative functional outcomes and clinical improvement. This study aims to determine whether urinary CTGF may serve as a non-invasive biomarker of bladder fibrosis and a potential predictor of surgical treatment response in patients with BPO.",[63,27,26],"Benign Prostatic Hyperplasia","NOT_YET_RECRUITING","2026-02-10",{"date":67,"type":41},"2026-02-18",{"date":69,"type":19},"2026-04-01",{"date":71,"type":19},"2026-12-01",{"name":73,"class":48},"Tarik Emre Sener",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100597202","association-between-qmaxegfr-ratio-and-luts-severity-in-men-over-40-100597202","NCT07055425","Association Between Qmax\u002FeGFR Ratio and LUTS Severity in Men Over 40","The Role of Qmax\u002FeGFR Ratio in Assessing Symptom Severity and QoL in Men Over 40 With LUTS","Inclusion Criteria:\n\n* Male patients aged 40 years or older presenting with lower urinary tract symptoms (LUTS)\n* Able to provide informed consent\n* Willing and able to undergo uroflowmetry and blood testing\n* Able to complete the IPSS questionnaire, including the QoL item\n* Estimated glomerular filtration rate (eGFR) ≥ 30 mL\u002Fmin\u002F1.73m²\n\nExclusion Criteria:\n\n* History of urological surgery (e.g., prostatectomy, bladder surgery)\n* Diagnosed or suspected prostate cancer\n* Active urinary tract infection (based on clinical symptoms or urinalysis)\n* Neurological conditions affecting bladder function (e.g., Parkinson's disease, spinal cord injury)\n* Presence of an indwelling urinary catheter at enrollment\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²\n* Inability to perform uroflowmetry or complete clinical evaluations",{"count":82,"type":19},100,"This study will look at how well a measure called the Qmax\u002FeGFR ratio is related to the severity of urination problems in men over the age of 40. Qmax is a test that shows how fast a person can urinate, and eGFR is a number that reflects kidney function. Men who have urinary symptoms will be asked to do a urine flow test, a blood test, and fill out a questionnaire about their symptoms and quality of life. We will study if there is a link between the Qmax\u002FeGFR ratio and how severe their symptoms are. The results may help doctors better understand how kidney and urinary function are related in men with these problems.",[26,85,86,87,88],"Voiding Dysfunction","Male Urological Health","Renal Function","Benign Prostate Obstruction (BPO)",[26,88,86,85,90],"Aging Male","2025-08-30",{"date":93,"type":41},"2025-09-05",{"date":95,"type":19},"2025-09-01",{"date":97,"type":19},"2026-05-01",{"name":99,"class":48},"Marmara University",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100596602","uroflowmetry-and-ipss-factors-influencing-surgical-decision-100596602","NCT07047599","Uroflowmetry and IPSS Factors Influencing Surgical Decision","Assessment of Clinical and Uroflowmetry Parameters as Predictors of Surgical Preference in Male Patients With Lower Urinary Tract Symptoms: A Prospective Observational Study","Inclusion Criteria:\n\n* Male patients aged 40 years and older\n* Presenting with lower urinary tract symptoms (LUTS)\n* Able to complete the IPSS questionnaire\n* Undergoing uroflowmetry as part of routine evaluation\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* History of urological surgery (e.g., TURP, HoLEP, radical prostatectomy)\n* Presence of known prostate or bladder cancer\n* Active urinary tract infection at the time of evaluation\n* Neurological conditions affecting voiding (e.g., Parkinson's disease, spinal cord injury)\n* Inability to perform uroflowmetry or incomplete IPSS data",{"count":82,"type":19},"This study aims to identify which symptoms or test findings lead men with lower urinary tract symptoms (LUTS) to consider surgical treatment. Male patients who visit the outpatient clinic for LUTS will be asked whether they would consider surgery in the future if their symptoms persist. Along with this, symptom severity scores (IPSS), quality of life scores, and uroflowmetry measurements such as maximum flow rate (Qmax) and post-void residual volume (PVR) will be collected. The goal is to determine which factors are most strongly associated with a desire for surgery. This is an observational, non-interventional study.",[26,88,85],[111,88,85,35,112],"Lower Urinary Tract Symptoms","Urolfowmetry",{"date":93,"type":41},{"date":115,"type":19},"2025-09-15",{"date":117,"type":19},"2026-06-01",{"name":99,"class":48},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100592137","clinical-outcomes-and-ejaculatory-function-in-bpo-patients-treated-with-silodosin-100592137","NCT06989515","Clinical Outcomes and Ejaculatory Function in BPO Patients Treated With Silodosin","Does Anejaculation Reflect Better Clinical Outcomes in BPO Patients Receiving Silodosin?","Inclusion Criteria:\n\n* Male patients aged 40 years or older\n* Diagnosed with lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO)\n* Initiating silodosin 8 mg\u002Fday therapy for the first time\n* Able to complete IPSS and IIEF-5 questionnaires\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* History of prior treatment with silodosin or other α-blockers in the last 3 months\n* Known neurogenic bladder or history of neurological disease affecting voiding\n* History of prostate surgery or pelvic radiation\n* Diagnosed prostate or bladder malignancy\n* Use of medications affecting sexual function (e.g., PDE5 inhibitors) within the last month\n* Severe cardiovascular, hepatic, or renal comorbidities\n* Cognitive impairment preventing informed consent or questionnaire completion",{"count":82,"type":19},"This observational study aims to evaluate the relationship between silodosin-induced anejaculation and clinical outcomes in male patients with benign prostatic obstruction (BPO). Silodosin is a commonly used alpha-blocker for lower urinary tract symptoms (LUTS). However, it may cause ejaculatory dysfunction, particularly anejaculation. In this study, patients receiving silodosin for the first time will be grouped based on whether they experience anejaculation or not. Treatment response will be assessed using urinary flow rate, post-void residual urine, and International Prostate Symptom Score (IPSS). Sexual function will be evaluated using the International Index of Erectile Function-5 (IIEF-5) before and after treatment. The study aims to explore whether the presence of anejaculation is associated with improved symptom relief or differences in sexual health.",[88,26,129,130,131],"Ejaculatory Dysfunction","Anejaculation","Silodosin",[131,129,133,111,134],"Benign Prostatic Obstruction","Alpha-blocker Side Effects","2025-06-04",{"date":137,"type":41},"2025-06-05",{"date":139,"type":19},"2025-06-15",{"date":141,"type":19},"2026-06-12",{"name":99,"class":48}]